4.5 Review

Blood-brain barrier transport of therapeutics via receptor-mediation

Journal

PHARMACEUTICAL RESEARCH
Volume 24, Issue 9, Pages 1759-1771

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-007-9379-0

Keywords

antibody; blood-brain barrier; brain drug delivery; transcytosis

Funding

  1. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052649] Funding Source: NIH RePORTER
  2. NINDS NIH HHS [NS052649, R01 NS052649-03, R01 NS052649] Funding Source: Medline

Ask authors/readers for more resources

Drug delivery to the brain is hindered by the presence of the blood-brain barrier (BBB). Although the BBB restricts the passage of many substances, it is actually selectively permeable to nutrients necessary for healthy brain function. To accomplish the task of nutrient transport, the brain endothelium is endowed with a diverse collection of molecular transport systems. One such class of transport system, known as a receptor-mediated transcytosis (RMT), employs the vesicular trafficking machinery of the endothelium to transport substrates between blood and brain. If appropriately targeted, RMT systems can also be used to shuttle a wide range of therapeutics into the brain in a noninvasive manner. Over the last decade, there have been significant developments in the arena of RMT-based brain drug transport, and this review will focus on those approaches that have been validated in an in vivo setting.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available